CSF_PsA_Highlights Brochure_ACR2022

More documents

Recommendations

Info

Key Presentations Saturday, 12 November 2022 13:00– 15:00 0308 13:00– 15:00 0380 0391 0395 POSTER SESSION RA – TREATMENT POSTER I Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies Joseph Merola POSTER SESSION SPONDYLOARTHRITIS INCLUDING PSA – DIAGNOSIS, MANIFESTATIONS, AND OUTCOMES POSTER I Changes in Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Ixekizumab in a Real-World US Cohort William Tillett Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data William Tillett How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study Uta Kiltz Sunday, 13 November 2022 09:00– 10:30 1006 09:00– 10:30 1035 1036 1040 1042 1043 13:00– 15:00 1493 POSTER SESSION SPONDYLOARTHRITIS INCLUDING PSA – DIAGNOSIS, MANIFESTATIONS, AND OUTCOMES POSTER II Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies Renaud Felten POSTER SESSION SPONDYLOARTHRITIS INCLUDING PSA – TREATMENT POSTER II: MIXED Efficacy of Guselkumab in Three Cohorts of Biologic- Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies Philip J Mease Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by History of Cigarette Smoking Alexis Ogdie Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis Uta Kiltz Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis Atul Deodhar Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis Jan Brandt-Juergens POSTER SESSION SPONDYLOARTHRITIS INCLUDING PSA – DIAGNOSIS, MANIFESTATIONS, AND OUTCOMES POSTER III Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry Philip J Mease
Chair’s Picks 1504 1509 15:00– 15:10 1597 15:15– 15:25 1598 15:30– 15:40 1599 Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement Lars Erik Kristensen Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations Xenofon Baraliakos ORAL SESSION ABSTRACTS: SPONDYLOARTHRITIS INCLUDING PSA – TREATMENT II: PSA Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial Frank Behrens ORAL SESSION ABSTRACTS: SPONDYLOARTHRITIS INCLUDING PSA – TREATMENT II: PSA Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial Philip Mease ORAL SESSION ABSTRACTS: SPONDYLOARTHRITIS INCLUDING PSA – TREATMENT II: PSA Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Joseph Merola Monday, 14 November 2022 13:00– 15:00 1850 13:00– 15:00 2127 2128 2129 2131 2132 2133 2134 POSTER SESSION MISCELLANEOUS RHEUMATIC AND INFLAMMATORY DISEASES POSTER III Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2 Jeffery Curtis POSTER SESSION SPONDYLOARTHRITIS INCLUDING PSA – TREATMENT POSTER III Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years Laura Coates Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics Joseph Merola Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Posthoc Analysis from a Phase 3, Randomized, Doubleblind, Placebo-controlled Study Through 2 Years Signe Holm Nielsen Minimal Disease Activity Response Patterns in Bio- Naïve Patients Treated with Guselkumab: A Machine Learning Analysis Alen Zabotti Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis Roy Fleischmann Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis Christopher Ritchlin Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program Richard Warren
Page 1: ACR 2022 Congress Preview PsA Steer

CSF_PsA_Highlights Brochure_ACR2022

Create successful ePaper yourself

Delete template?

Save as template?